Evidence map›Paper›PMID 34051886›Full record

Trial reportThe Lancet. Infectious diseases2021

Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial.

Boris Revollo, Ignacio Blanco, Pablo Soler, Jessica Toro, Nuria Izquierdo-Useros, Jordi Puig, Xavier Puig, Valentí Navarro-Pérez, Cristina Casañ, Lidia Ruiz and 4 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Lancet. Infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04668625 (Risk of Infection of SARS-CoV-2 in a Massive Musical Show With Transmission Prevention Measures), which is not on this map. Cited by 54 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 4 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04668625 nacompletednot on this map

Risk of Infection of SARS-CoV-2 in a Massive Musical Show With Transmission Prevention Measures: Randomized Study

TypeinterventionalSponsorFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaRan2020 to 2021Enrolled1,000ConditionsCOVID-19 (SARS-CoV-2)ArmsParticipate in a massive musical event
3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 4 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.The Cochrane database of systematic reviews · 2022
    Pooled it
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Lessons Learned from In-Person Conferences in the Times of COVID-19.International journal of environmental research and public health · 2022
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Boris RevolloDivision of Infectious diseases and Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias i Pujol, Badalona, Spain.
Ignacio BlancoMetropolitana Nord Laboratory, Institut Català de la Salut, Badalona, Spain.
Pablo SolerPrimavera Sound Group, Barcelona, Spain.
Jessica ToroDivision of Infectious diseases and Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias i Pujol, Badalona, Spain.
Nuria Izquierdo-UserosIrsiCaixa AIDS Research Institute, University Hospital Germans Trias i Pujol, Badalona, Spain; Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Spain.
Jordi PuigDivision of Infectious diseases and Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias i Pujol, Badalona, Spain.
Xavier PuigDepartment of Statistics and Operations Research, Universitat Politècnica de Catalunya-BarcelonaTech, Barcelona, Spain.
Valentí Navarro-PérezClinical Research Unit, Institut Català d'Oncologia, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Cristina CasañMetropolitana Nord Laboratory, Institut Català de la Salut, Badalona, Spain.
Lidia RuizIrsiCaixa AIDS Research Institute, University Hospital Germans Trias i Pujol, Badalona, Spain.
Daniel Perez-ZsoltIrsiCaixa AIDS Research Institute, University Hospital Germans Trias i Pujol, Badalona, Spain; Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Spain.
Sebastià VidelaDivision of Infectious diseases and Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias i Pujol, Badalona, Spain; Clinical Research Support Unit, Clinical Pharmacology Department, Bellvitge University Hospital, University of Barcelona, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Bonaventura ClotetDivision of Infectious diseases and Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias i Pujol, Badalona, Spain; IrsiCaixa AIDS Research Institute, University Hospital Germans Trias i Pujol, Badalona, Spain; Universitat de Vic-Universitat Central de Catalunya (UVIC-UCC), Vic, Spain; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
Josep M LlibreDivision of Infectious diseases and Foundation for Fighting AIDS, Infectious Diseases and Promoting Health and Science, University Hospital Germans Trias i Pujol, Badalona, Spain. Electronic address: jmllibre@flsida.org.
Fundació Lluita contra les Infeccions · ESInstitut Català de la Salut · ESIrsiCaixa · ESBellvitge University Hospital · ESConsorci d’Atenció Primària de Salut Barcelona Esquerra · ESInstitut d'Investigació Biomédica de Bellvitge · ESInstitut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESUniversitat Politècnica de Catalunya · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe banning of mass-gathering indoor events to prevent SARS-CoV-2 spread has had an important effect on local economies. Despite growing evidence on the suitability of antigen-detecting rapid diagnostic tests (Ag-RDT) for mass screening at the event entry, this strategy has not been assessed under controlled conditions. We aimed to assess the effectiveness of a prevention strategy during a live indoor concert.

methodsWe designed a randomised controlled open-label trial to assess the effectiveness of a comprehensive preventive intervention for a mass-gathering indoor event (a live concert) based on systematic same-day screening of attendees with Ag-RDTs, use of facial masks, and adequate air ventilation. The event took place in the Sala Apolo, Barcelona, Spain. Adults aged 18-59 years with a negative result in an Ag-RDT from a nasopharyngeal swab collected immediately before entering the event were randomised 1:1 (block randomisation stratified by age and gender) to either attend the indoor event for 5 hours or go home. Nasopharyngeal specimens used for Ag-RDT screening were analysed by real-time reverse-transcriptase PCR (RT-PCR) and cell culture (Vero E6 cells). 8 days after the event, a nasopharyngeal swab was collected and analysed by Ag-RDT, RT-PCR, and a transcription-mediated amplification test (TMA). The primary outcome was the difference in incidence of RT-PCR-confirmed SARS-CoV-2 infection at 8 days between the control and the intervention groups, assessed in all participants who were randomly assigned, attended the event, and had a valid result for the SARS-CoV-2 test done at follow-up. The trial is registered at ClinicalTrials.gov, NCT04668625.

findingsParticipant enrollment took place during the morning of the day of the concert, Dec 12, 2020. Of the 1140 people who responded to the call and were deemed eligible, 1047 were randomly assigned to either enter the music event (experimental group) or continue with normal life (control group). Of the 523 randomly assigned to the experimental group, 465 were included in the analysis of the primary outcome (51 did not enter the event and eight did not take part in the follow-up assessment), and of the 524 randomly assigned to the control group, 495 were included in the final analysis (29 did not take part in the follow-up). At baseline, 15 (3%) of 495 individuals in the control group and 13 (3%) of 465 in the experimental group tested positive on TMA despite a negative Ag-RDT result. The RT-PCR test was positive in one case in each group and cell viral culture was negative in all cases. 8 days after the event, two (<1%) individuals in the control arm had a positive Ag-RDT and PCR result, whereas no Ag-RDT nor RT-PCR positive results were found in the intervention arm. The Bayesian estimate for the incidence between the experimental and control groups was -0·15% (95% CI -0·72 to 0·44).

interpretationOur study provides preliminary evidence on the safety of indoor mass-gathering events during a COVID-19 outbreak under a comprehensive preventive intervention. The data could help restart cultural activities halted during COVID-19, which might have important sociocultural and economic implications.

fundingPrimavera Sound Group and the #YoMeCorono Initiative. TRANSLATION: For the Spanish translation of the abstract see Supplementary Materials section.

Indexed as

COVID-19AdolescentAdultCOVID-19 Serological TestingHumansMass ScreeningMiddle AgedReproducibility of ResultsSpainYoung Adult

Identifiers

PMID34051886
PMCPMC8457773
OpenAlexW3164807805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.